Free Trial
NASDAQ:BRNS

Barinthus Biotherapeutics Q2 2024 Earnings Report

Barinthus Biotherapeutics logo
$0.84 +0.02 (+1.94%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$0.78 -0.05 (-6.56%)
As of 04/28/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Barinthus Biotherapeutics EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.42
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Barinthus Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Barinthus Biotherapeutics Announcement Details

Quarter
Q2 2024
Time
Before Market Opens
Conference Call Date
Wednesday, August 7, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Barinthus Biotherapeutics' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Barinthus Biotherapeutics Earnings Headlines

Real Americans Don’t Wait on Wall Street’s Next Move
What's happening in the markets right now should concern every freedom-loving American who's worked hard and saved smart. Your 401(k) doesn't deserve to be dragged through the mud by tariffs, trade wars, reckless spending, and political standoffs. And you don't have to stand by while Wall Street plays roulette with your future.
William Blair Remains a Buy on Barinthus Biotherapeutics (BRNS)
See More Barinthus Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Barinthus Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Barinthus Biotherapeutics and other key companies, straight to your email.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics (NASDAQ:BRNS), a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

View Barinthus Biotherapeutics Profile

More Earnings Resources from MarketBeat